TWI878811B - 用於治療病毒感染的化合物及方法 - Google Patents

用於治療病毒感染的化合物及方法 Download PDF

Info

Publication number
TWI878811B
TWI878811B TW112107366A TW112107366A TWI878811B TW I878811 B TWI878811 B TW I878811B TW 112107366 A TW112107366 A TW 112107366A TW 112107366 A TW112107366 A TW 112107366A TW I878811 B TWI878811 B TW I878811B
Authority
TW
Taiwan
Prior art keywords
infection
virus
compound
therapeutic agent
additional therapeutic
Prior art date
Application number
TW112107366A
Other languages
English (en)
Chinese (zh)
Other versions
TW202345786A (zh
Inventor
千炳權
羅歐 V 卡拉
李查德 麥克曼
Original Assignee
美商基利科學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商基利科學股份有限公司 filed Critical 美商基利科學股份有限公司
Publication of TW202345786A publication Critical patent/TW202345786A/zh
Application granted granted Critical
Publication of TWI878811B publication Critical patent/TWI878811B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
TW112107366A 2022-03-02 2023-03-01 用於治療病毒感染的化合物及方法 TWI878811B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263315919P 2022-03-02 2022-03-02
US63/315,919 2022-03-02
US202263413748P 2022-10-06 2022-10-06
US63/413,748 2022-10-06

Publications (2)

Publication Number Publication Date
TW202345786A TW202345786A (zh) 2023-12-01
TWI878811B true TWI878811B (zh) 2025-04-01

Family

ID=85772852

Family Applications (2)

Application Number Title Priority Date Filing Date
TW112107366A TWI878811B (zh) 2022-03-02 2023-03-01 用於治療病毒感染的化合物及方法
TW114109499A TW202525811A (zh) 2022-03-02 2023-03-01 用於治療病毒感染的化合物及方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW114109499A TW202525811A (zh) 2022-03-02 2023-03-01 用於治療病毒感染的化合物及方法

Country Status (8)

Country Link
US (1) US20230322813A1 (https=)
EP (1) EP4486746A1 (https=)
JP (1) JP2025508943A (https=)
KR (1) KR20240154646A (https=)
AU (1) AU2023227470A1 (https=)
CA (1) CA3243944A1 (https=)
TW (2) TWI878811B (https=)
WO (1) WO2023167938A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
CA3059777C (en) 2017-05-01 2023-02-21 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
KR20220153619A (ko) 2020-03-12 2022-11-18 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오사이드의 제조 방법
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN119039322A (zh) * 2023-09-19 2024-11-29 广东晨康生物科技有限公司 一种环碳酸酯核苷化合物的盐、晶体及其制备方法和应用
CN119792537B (zh) * 2025-01-22 2025-10-21 常州大学 利巴韦林与pd-1抑制剂联合用药物组合物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017184668A1 (en) * 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
WO2021154687A1 (en) * 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
WO2021167882A1 (en) * 2020-02-18 2021-08-26 Gilead Sciences, Inc. Antiviral compounds
CN113735862A (zh) * 2020-12-30 2021-12-03 南方科技大学 一种治疗病毒感染的核苷类化合物及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
JP5030587B2 (ja) 2003-06-26 2012-09-19 バイオトロン・リミテッド 抗ウイルスアシルグアニジン化合物および方法
EP2826770B1 (en) 2005-06-24 2018-09-12 Biotron Limited Acylguanidine compounds with antiviral activity
US20100254942A1 (en) 2007-08-03 2010-10-07 Biotron Limited Hepatitis c antiviral compositions and methods
CA2881322A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
SI3043865T1 (sl) 2013-09-11 2021-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B
EA201691261A1 (ru) 2014-01-30 2016-11-30 Ф. Хоффманн-Ля Рош Аг Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
AU2015226206B2 (en) 2014-03-07 2017-03-16 F. Hoffmann-La Roche Ag Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
KR20160148715A (ko) 2014-05-13 2016-12-26 에프. 호프만-라 로슈 아게 B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 다이하이드로퀴놀리진온
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
BR112017002970B1 (pt) 2014-08-14 2023-04-11 F. Hoffmann-La Roche Ag Novas piridazonas e triazinonas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
AR103222A1 (es) 2014-12-23 2017-04-26 Hoffmann La Roche Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
CN107108610B (zh) 2014-12-30 2019-06-04 豪夫迈·罗氏有限公司 用于治疗和预防肝炎b病毒感染的新的四氢吡啶并嘧啶和四氢吡啶并吡啶化合物
CN107109497A (zh) 2014-12-31 2017-08-29 豪夫迈·罗氏有限公司 通过实时PCR从细胞裂解物定量HBV cccDNA的高通量新方法
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
WO2016120186A1 (en) 2015-01-27 2016-08-04 F. Hoffmann-La Roche Ag Recombinant hbv cccdna, the method to generate thereof and the use thereof
HK1244281B (zh) 2015-02-11 2020-02-07 F. Hoffmann-La Roche Ag 治疗和预防乙型肝炎病毒感染的2-氧代-6,7-二氢苯并[a]喹嗪-3-甲酸衍生物
SG11201907034PA (en) 2017-02-08 2019-08-27 Biotron Ltd Methods of treating influenza
CN112778310B (zh) * 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
IL300453A (en) * 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
US20240166680A1 (en) * 2021-04-15 2024-05-23 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Nucleoside analog and use thereof
CN114181258B (zh) * 2021-12-29 2023-10-13 南京师范大学 用于抗病毒治疗的核苷类化合物及用途
CN114437159B (zh) * 2022-04-11 2022-06-28 佛山市晨康生物科技有限公司 一种环状碳酸酯核苷类化合物及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017184668A1 (en) * 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
WO2021154687A1 (en) * 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
WO2021167882A1 (en) * 2020-02-18 2021-08-26 Gilead Sciences, Inc. Antiviral compounds
CN113735862A (zh) * 2020-12-30 2021-12-03 南方科技大学 一种治疗病毒感染的核苷类化合物及其用途

Also Published As

Publication number Publication date
EP4486746A1 (en) 2025-01-08
WO2023167938A1 (en) 2023-09-07
KR20240154646A (ko) 2024-10-25
TW202525811A (zh) 2025-07-01
CA3243944A1 (en) 2023-09-07
JP2025508943A (ja) 2025-04-10
AU2023227470A1 (en) 2024-08-29
TW202345786A (zh) 2023-12-01
US20230322813A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
US12297226B2 (en) Compounds and methods for treatment of viral infections
TWI878811B (zh) 用於治療病毒感染的化合物及方法
TWI867455B (zh) 用於治療病毒感染的化合物及方法
WO2023239665A1 (en) Methods for treatment of viral infections including sars-cov-2
TW202517647A (zh) 用於治療病毒感染的化合物及方法
CN118786127A (zh) 用于治疗病毒感染的化合物和方法
HK40113783A (zh) 用於治疗病毒感染的化合物和方法
HK40115603A (en) Compounds and methods for treatment of viral infections
EA048943B1 (ru) Соединения и способы лечения вирусных инфекций
HK40096334A (en) Compounds and methods for treatment of viral infections
HK40096334B (en) Compounds and methods for treatment of viral infections
TW202525807A (zh) 抗病毒化合物及其製造及使用方法
HK40096728B (zh) 用於治疗病毒感染的化合物和方法
HK40096728A (zh) 用於治疗病毒感染的化合物和方法